Quality of life assessment during chemotherapy for non-small cell lung cancer

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

“…In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40]. Limited evaluation of quality of life failed to show any significant difference in one study [42], However, as shown also in our study, there can be considerable symptomatic relief even in the absence of objective responses [47], We conclude that the acceptable antitumor activity of 'FOM', combined with its very low toxicity, makes this regimen attrac tive for all patients in whom improvement of quality of life rather than response is the main goal of treatment. 'FOM' should be tested in a randomized trial versus current cisplatinand/or anthracycline-based combinations for advanced NSCLC, evaluating primarily quality of life and including a control arm with best supportive care.…”

“…In most instances, this has been balanced by increas ed toxicity and a generally lower quality of life. Insufficient emphasis has been placed so far upon the evaluation of the patient's quality of life in addition to attempted benefits and toxic effects of chemotherapy [47]. In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40].…”

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

“…In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40]. Limited evaluation of quality of life failed to show any significant difference in one study [42], However, as shown also in our study, there can be considerable symptomatic relief even in the absence of objective responses [47], We conclude that the acceptable antitumor activity of 'FOM', combined with its very low toxicity, makes this regimen attrac tive for all patients in whom improvement of quality of life rather than response is the main goal of treatment. 'FOM' should be tested in a randomized trial versus current cisplatinand/or anthracycline-based combinations for advanced NSCLC, evaluating primarily quality of life and including a control arm with best supportive care.…”

“…In most instances, this has been balanced by increas ed toxicity and a generally lower quality of life. Insufficient emphasis has been placed so far upon the evaluation of the patient's quality of life in addition to attempted benefits and toxic effects of chemotherapy [47]. In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40].…”

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

“…Statements on palliative effects from treatment often pertain to physicians' ratings of performance status (Bakker et al, 1986;Ganz et al, 1989;Minet et al, 1987), although conclusive data on quality of life based upon patient self-ratings are sparse (BartelCopel et al, 1997). Nevertheless, several recent publications and reports on NSCLC have incorporated quality-of-life assessment in the treatment evaluation Maasilta et al, 1990;Sarna, 1990;Kosty et al, 1994;Pujol et al, 1994;Billingham et al, 1997;Helsing et al, 1998), indicating an increasing awareness of one of the primary therapeutic goals with currently available regimens, i.e. palliation.…”

Dyspnea, Anxiety, Body Consciousness, and Quality of Life in Patients with Lung Cancer

“…14 Although it has been documented that dyspnea can negatively influence QOL, 8,9,15,16 the literature describing the relationship between these two very complex phenomena in cancer patients is scant and difficult to interpret. 11 Among patients with pulmonary disease, including lung cancer, correlations have been made between diminished life quality and advanced stage, 17,18 poor performance status, 7,[17][18][19][20] specific treatment regimens, 16,17,[20][21][22][23][24] disease symptoms, [23][24][25] hypoxemia, 20,26 and female gender. 7,18 Yet, there is very little literature that comprehensively and systematically describes the relationship between dyspnea perceptions and life quality in cancer patients specifically, or in the smaller subset of patients with lung cancer.…”

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

“…In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40]. Limited evaluation of quality of life failed to show any significant difference in one study [42], However, as shown also in our study, there can be considerable symptomatic relief even in the absence of objective responses [47], We conclude that the acceptable antitumor activity of 'FOM', combined with its very low toxicity, makes this regimen attrac tive for all patients in whom improvement of quality of life rather than response is the main goal of treatment. 'FOM' should be tested in a randomized trial versus current cisplatinand/or anthracycline-based combinations for advanced NSCLC, evaluating primarily quality of life and including a control arm with best supportive care.…”

“…In most instances, this has been balanced by increas ed toxicity and a generally lower quality of life. Insufficient emphasis has been placed so far upon the evaluation of the patient's quality of life in addition to attempted benefits and toxic effects of chemotherapy [47]. In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40].…”

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

“…Statements on palliative effects from treatment often pertain to physicians' ratings of performance status (Bakker et al, 1986;Ganz et al, 1989;Minet et al, 1987), although conclusive data on quality of life based upon patient self-ratings are sparse (BartelCopel et al, 1997). Nevertheless, several recent publications and reports on NSCLC have incorporated quality-of-life assessment in the treatment evaluation Maasilta et al, 1990;Sarna, 1990;Kosty et al, 1994;Pujol et al, 1994;Billingham et al, 1997;Helsing et al, 1998), indicating an increasing awareness of one of the primary therapeutic goals with currently available regimens, i.e. palliation.…”

Dyspnea, Anxiety, Body Consciousness, and Quality of Life in Patients with Lung Cancer

“…14 Although it has been documented that dyspnea can negatively influence QOL, 8,9,15,16 the literature describing the relationship between these two very complex phenomena in cancer patients is scant and difficult to interpret. 11 Among patients with pulmonary disease, including lung cancer, correlations have been made between diminished life quality and advanced stage, 17,18 poor performance status, 7,[17][18][19][20] specific treatment regimens, 16,17,[20][21][22][23][24] disease symptoms, [23][24][25] hypoxemia, 20,26 and female gender. 7,18 Yet, there is very little literature that comprehensively and systematically describes the relationship between dyspnea perceptions and life quality in cancer patients specifically, or in the smaller subset of patients with lung cancer.…”

FOM: An Effective, Non-Cisplatin-Based Combination Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity

“…In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40]. Limited evaluation of quality of life failed to show any significant difference in one study [42], However, as shown also in our study, there can be considerable symptomatic relief even in the absence of objective responses [47], We conclude that the acceptable antitumor activity of 'FOM', combined with its very low toxicity, makes this regimen attrac tive for all patients in whom improvement of quality of life rather than response is the main goal of treatment. 'FOM' should be tested in a randomized trial versus current cisplatinand/or anthracycline-based combinations for advanced NSCLC, evaluating primarily quality of life and including a control arm with best supportive care.…”

“…In most instances, this has been balanced by increas ed toxicity and a generally lower quality of life. Insufficient emphasis has been placed so far upon the evaluation of the patient's quality of life in addition to attempted benefits and toxic effects of chemotherapy [47]. In fact, attempts to measure quality of life encountered difficulty because of compliance problems [38,39] or were not undertaken [35,40].…”

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

“…Statements on palliative effects from treatment often pertain to physicians' ratings of performance status (Bakker et al, 1986;Ganz et al, 1989;Minet et al, 1987), although conclusive data on quality of life based upon patient self-ratings are sparse (BartelCopel et al, 1997). Nevertheless, several recent publications and reports on NSCLC have incorporated quality-of-life assessment in the treatment evaluation Maasilta et al, 1990;Sarna, 1990;Kosty et al, 1994;Pujol et al, 1994;Billingham et al, 1997;Helsing et al, 1998), indicating an increasing awareness of one of the primary therapeutic goals with currently available regimens, i.e. palliation.…”

Dyspnea, Anxiety, Body Consciousness, and Quality of Life in Patients with Lung Cancer

“…14 Although it has been documented that dyspnea can negatively influence QOL, 8,9,15,16 the literature describing the relationship between these two very complex phenomena in cancer patients is scant and difficult to interpret. 11 Among patients with pulmonary disease, including lung cancer, correlations have been made between diminished life quality and advanced stage, 17,18 poor performance status, 7,[17][18][19][20] specific treatment regimens, 16,17,[20][21][22][23][24] disease symptoms, [23][24][25] hypoxemia, 20,26 and female gender. 7,18 Yet, there is very little literature that comprehensively and systematically describes the relationship between dyspnea perceptions and life quality in cancer patients specifically, or in the smaller subset of patients with lung cancer.…”